Acceleron Offers Updated Results From Ongoing Phase 2 Trials Of Luspatercept In Patients With Beta-Thalassemia, Showed 51% (16 Of 30) Patients Achieved ≥ 1 gram per deciliter increase in hemoglobin in the fixed 12-week intervals including weeks 13-24'